#USA #New York #Securities Fraud #Rosen Law Firm #Unicycive Therapeutics

Investors Encourage to Lead Class Action Against Unicycive Therapeutics

On September 29, 2025, the Rosen Law Firm, renowned for its role in protecting investors' rights, announced a crucial call to action for those who purchased securities from Unicycive Therapeutics, Inc. (NASDAQ: UNCY) during the specified class period from March 29, 2024, to June 27, 2025. This period marks the timeframe wherein significant developments regarding the alleged securities fraud took place.

Important Deadline for Investors

The law firm highlights that the deadline to apply as a lead plaintiff is October 14, 2025. This designation is vital as the lead plaintiff serves as a representative for other members of the class, guiding the litigation process. Investors who acquired Unicycive securities within the indicated timeframe have the opportunity to seek compensation for any financial losses incurred due to the alleged fraudulent activities.

No Upfront Costs

Rosen Law Firm reassures potential participants that they can join this class action without any out-of-pocket expenses. The firm operates on a contingency fee basis, meaning that fees are only collected when the case is successfully resolved. This approach eliminates financial barriers, allowing more investors to participate in the legal proceedings.

How to Join the Action

Interested investors can take immediate steps to join the class action by visiting the Rosen Law Firm’s designated webpage or contacting attorney Phillip Kim via telephone or email. The process is straightforward and designed to be accessible for those affected.

Allegations Against Unicycive Therapeutics

The legal action presents allegations that Unicycive and its representatives provided misleading statements about the company’s capability to meet FDA manufacturing compliance requirements, as well as the regulatory prospects of its New Drug Application (NDA) for oxylanthanum carbunate (OLC). These misrepresentations purportedly resulted in detrimental consequences for investors once the reality of the situation came to light.

Track Record of Rosen Law Firm

The Rosen Law Firm is not unfamiliar with handling cases in this domain, boasting a strong track record of success in securities class actions. The firm has been recognized for securing substantial settlements for investors and has consistently ranked among the top firms in related litigations. Notably, they achieved a historic settlement against a Chinese company, which highlights their proficiency in navigating complex securities fraud cases.

Furthermore, the firm’s founding partner, Laurence Rosen, has earned accolades within the legal community, being named a Titan of the Plaintiffs' Bar by Law360 in 2020. Many of the attorneys associated with the firm have also been recognized as leaders in the field of securities litigation.

Recommendations for Investors

Investors are advised to exercise caution when choosing legal representation for securities class actions. Rosen Law Firm encourages those affected to be diligent in selecting experienced counsel, as not all firms possess the necessary expertise or recognition in securities litigation. Engaging a qualified attorney can significantly influence the direction and outcome of such a lawsuit.

Conclusion

For those who invested in Unicycive Therapeutics during the specified class period, now is a critical time to consider their options regarding the ongoing securities fraud lawsuit. With legal representation from a recognized firm like Rosen Law Firm, investors can not only hold the company accountable but also seek to recover their losses while contributing to a collective legal effort. The announcement stresses the communal nature of this class action, inviting all eligible investors to take part in seeking justice for their grievances.

To stay updated on the developments of this case and for more information, connect with the Rosen Law Firm through their social media channels.